Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".

Whereas Hidradenitis Suppurativa (in this resolution referred to as HS) is a chronic, inflammatory skin disease that affects approximately 3,300,000 people in the United States;
Whereas HS causes painful, boil-like nodules and abscesses anywhere on the body, and can progress to form tunnels under the skin and cause extensive scarring;
Whereas individuals with HS frequently suffer from 5 primary domains of physical and emotional suffering, pain, drainage, odor, itching, and profound psychological distress;
Whereas HS is associated with one of the highest completed suicide rates among dermatological diseases, second only to melanoma;
Whereas 75 percent of individuals with HS are misdiagnosed or not diagnosed until after age 25, missing critical windows for early intervention and care;
Whereas delayed diagnosis contributes to worsening disease progression, higher healthcare costs, avoidable emergency room visits, and unnecessary procedures;
Whereas individuals are often diagnosed with HS in the prime of their lives, affecting their ability to work, maintain relationships, and participate fully in society;
Whereas there are currently only 3 biologic therapies approved by the Food and Drug Administration for the treatment of HS;
Whereas additional research is urgently needed to develop new treatments, understand the pathogenesis of the disease, identify biomarkers of HS, and improve outcomes for HS patients;
Whereas Federal policy can play a critical role in improving access to biologic therapies, wound care, and comprehensive care for HS patients; and
Whereas designating the first week of June as Hidradenitis Suppurativa Awareness Week would increase public awareness, foster understanding, and catalyze progress in diagnosing, treating, and ultimately curing HS: Now, therefore, be it
That the House of Representatives—
supports the designation of Hidradenitis Suppurativa Awareness Week; and
recognizes the importance of—
increasing awareness and education about HS among the public and health professionals;
promoting timely and accurate diagnosis of HS through improved screening and culturally competent care;
supporting biomedical research to better understand HS pathogenesis, treatment efficacy, and long-term outcomes;
accelerating the development of effective treatments and expanding access to existing therapies for HS; and
advancing policies that improve access to care and quality of life for people living with HS and their caregivers.